Indication: Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

COG ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR)

Sub-indication: Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Drug Study

Principal Investigator: Kerry K. McGowan, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Children's Oncology Group (COG)

Search our entire site.